This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Ronopterin for Moderate to Severe Traumatic Brain Injury

< Back

Ronopterin for Moderate to Severe Traumatic Brain Injury


Neurology and Neurosurgery

January 2018

Traumatic brain injury is a form of brain injury that results from damage to the head or brain from an external force. This can affect cognitive, physical and psychosocial functioning temporarily or
permanently. Long-term impairment of these factors can lead to disability and loss of independence. The majority of people with head injuries are diagnosed with mild head injuries, however one fifth have features that suggest a more severe outcome of skull fracture or brain damage.

Ronopterin is being developed as a continuous infusion that can be used individually or in combination with the current standard treatments for traumatic brain injury. The current medications available are only used to treat the symptoms of traumatic brain injury. If licensed ronopterin has the potential to reduce the pressure build up in the skull and reduce brain inflammation. Therefore this could be the first medication licensed for the treatment of traumatic brain injury.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts